Neurocrine Biosciences | NBIX - Capital Social Ordinario





Capital Social Ordinario Cambio Fecha
AbbVie USD 1.77B 1.75B 2025-06
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 59.34M 892K 2026-03
ALKERMES USD 166.46M 855K 2026-03
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Amgen USD 540M 1000K 2026-03
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Cytokinetics USD 124.43M 2.17M 2026-03
Enanta Pharmaceuticals USD 212K 1000 2023-12
Exelixis USD 253.7M 8.78M 2026-03
Gilead Sciences USD 1.24B 1000K 2026-03
Halozyme Therapeutics USD 118.52M 741K 2026-03
Incyte USD 199.95M 1.49M 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.6M 500K 2026-03
Pfizer USD 5.7B 13M 2026-03
Prothena USD 53.08M 756K 2026-03
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Repligen USD 56.4M 74K 2026-03
Rigel Pharmaceuticals USD 17K 158K 2024-06
Sarepta Therapeutics USD 105.57M 607K 2026-03
Teva Pharmaceutical Industries USD 1.16B 16.72M 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03
Xoma USD 87K 1000 2024-06